Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Pearson, Andrew D. J. [VerfasserIn]   i
 Allen, Carl [VerfasserIn]   i
 Fangusaro, Jason [VerfasserIn]   i
 Hutter, Caroline [VerfasserIn]   i
 Witt, Olaf [VerfasserIn]   i
 Weiner, Susan [VerfasserIn]   i
 Reaman, Gregory [VerfasserIn]   i
 Russo, Mark [VerfasserIn]   i
 Bandopadhayay, Pratiti [VerfasserIn]   i
 Ahsan, Sama [VerfasserIn]   i
 Barone, Amy [VerfasserIn]   i
 Barry, Elly [VerfasserIn]   i
 de Rojas, Teresa [VerfasserIn]   i
 Fisher, Michael [VerfasserIn]   i
 Fox, Elizabeth [VerfasserIn]   i
 Bender, Julia Glade [VerfasserIn]   i
 Gore, Lia [VerfasserIn]   i
 Hargrave, Darren [VerfasserIn]   i
 Hawkins, Doug [VerfasserIn]   i
 Kreider, Brent [VerfasserIn]   i
 Langseth, Abraham J. [VerfasserIn]   i
 Lesa, Giovanni [VerfasserIn]   i
 Ligas, Franca [VerfasserIn]   i
 Marotti, Marcelo [VerfasserIn]   i
 Marshall, Lynley V. [VerfasserIn]   i
 Nasri, Kahina [VerfasserIn]   i
 Norga, Koen [VerfasserIn]   i
 Nysom, Karsten [VerfasserIn]   i
 Pappo, Alberto [VerfasserIn]   i
 Rossato, Gianluca [VerfasserIn]   i
 Scobie, Nicole [VerfasserIn]   i
 Smith, Malcolm [VerfasserIn]   i
 Stieglitz, Elliot [VerfasserIn]   i
 Weigel, Brenda [VerfasserIn]   i
 Weinstein, Amy [VerfasserIn]   i
 Viana, Ruth [VerfasserIn]   i
 Karres, Dominik [VerfasserIn]   i
 Vassal, Gilles [VerfasserIn]   i
Titel:Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors
Titelzusatz:ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Verf.angabe:Andrew DJ. Pearson, Carl Allen, Jason Fangusaro, Caroline Hutter, Olaf Witt, Susan Weiner, Gregory Reaman, Mark Russo, Pratiti Bandopadhayay, Sama Ahsan, Amy Barone, Elly Barry, Teresa de Rojas, Michael Fisher, Elizabeth Fox, Julia Glade Bender, Lia Gore, Darren Hargrave, Doug Hawkins, Brent Kreider, Abraham J. Langseth, Giovanni Lesa, Franca Ligas, Marcelo Marotti, Lynley V. Marshall, Kahina Nasri, Koen Norga, Karsten Nysom, Alberto Pappo, Gianluca Rossato, Nicole Scobie, Malcolm Smith, Elliot Stieglitz, Brenda Weigel, Amy Weinstein, Ruth Viana, Dominik Karres, Gilles Vassal
E-Jahr:2022
Jahr:14 October 2022
Umfang:23 S.
Fussnoten:Dateiversion vom 3. November 2022 ; Gesehen am 18.01.2023
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2022
Band/Heft Quelle:177(2022), Seite 120-142
ISSN Quelle:1879-0852
Abstract:As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK pathway inhibitors are being developed in adults. However, MAPK signals through many cascades and feedback loops and perturbing the MAPK pathway may have substantial influence on other pathways as well as normal development. In view of these issues, the ninth Paediatric Strategy Forum focused on MAPK inhibitors. Development of MAPK pathway inhibitors to date has been predominantly driven by adult indications such as malignant melanoma. However, these inhibitors may also target unmet needs in paediatric low-grade gliomas, high-grade gliomas, Langerhans cell histiocytosis, juvenile myelomonocytic leukaemia and several other paediatric conditions. Although MAPK inhibitors have demonstrated activity in paediatric cancer, the response rates and duration of responses needs improvement and better documentation. The rapid development and evaluation of combination approaches, based on a deep understanding of biology, is required to optimise responses and to avoid paradoxical tumour growth and other unintended consequences including severe toxicity. Better inhibitors with higher central nervous systempenetration for primary brain tumours and cancers with a propensity for central nervous system metastases need to be studied to determine if they are more effective than agents currently being used, and the optimum duration of therapy with MAPK inhibition needs to be determined.
DOI:doi:10.1016/j.ejca.2022.09.036
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2022.09.036
 Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922007766
 DOI: https://doi.org/10.1016/j.ejca.2022.09.036
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cancer therapeutics
 Drug development
 MAPK pathway inhibitors
 Paediatric oncology
 Paediatric strategy forum
K10plus-PPN:1831342022
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69007662   QR-Code
zum Seitenanfang